Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specialized in the development ...

LB-102 has potential to be the first benzamide approved for schizophrenia in the U.S. NOVA-2 trial to enroll approximately 460 patients Primary endpoint to evaluate change in PANSS total score at week ...

J&J was keen to highlight that these trial results do not invalidate tau as a therapeutic target for Alzheimer’s disease; the trial helps further understanding of tau pathology.

Engaging in a simple home-based exercise regimen of walking and resistance training during chemotherapy can help patients with cancer stay sharper and less fatigued, new data show.

Two large phase 3 trials found that oral semaglutide 14 mg did not slow cognitive or functional decline over 104 weeks in ...

The biomarker data presented at AD/PD 2026 from the Phase III APOLLOE4 trial showed that in the MCI subgroup, ...

Cognitive warfare technologies now model and simulate human behavior at scale, raising concerns about autonomous digital ...

With age, sleep becomes more shallow and intermittent — this is a natural process associated with changes in brain function and biological rhythms. However, in some cases, such changes may indicate ...

Artelo Biosciences, Inc. (NASDAQ: ARTL) is drawing increased attention following its expansion into the $16.3 billion glaucoma market through a fully funded investigator-sponsored clinical study—an ...

Despite a substantial increase in women’s collegiate sports participation in the United States over the last decade, 1 female-specific athletic research remains sparse, resulting in significant ...